Clinical Trials
4 trialsNCT01463891 2023-07-24
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Eisai Inc.
Completed
NCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT03058406 2020-04-06
HAL03T
Eisai Inc.
Completed
NCT03437083 2019-01-25
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Eisai Inc.
Completed